V. Charra et al. / Journal of Organometallic Chemistry xxx (2015) 1e9
7
Synthesis of 1,10-(1,3-phenylene)bis(3-butyl-1H-imidazol-3-ium)
bromide (1b) [95]
A procedure similar to that used for compound 1a with 1,3-
di(imidazol-1-yl)benzene (4.00 g, 19.0 mmol) and n-butyl bro-
mide (9.70 mL, 87.6 mmol), in refluxing THF, for 72 h, gave 1b, as an
off-white powder (5.78 g, 11.9 mmol). Yield: 63%. 1H NMR
J ¼ 7.3 Hz, 6H, CH3Bu). 13C{1H} NMR (126 MHz, CDCl3):
d
179.2
(Ccarbene), 141.0 (Caryl), 131.8 (CHaryl), 124.4 (CHaryl), 122.4 (CHimida-
zole), 122.3 (CHimidazole), 120.2 (CHaryl), 52.6 (NCH2Bu), 33.5 (CH2Bu),
19.9 (CHB2u), 13.8 (CH3Bu). Anal. Calc. for C20H26N4Ag2Cl2: C, 39.44; H,
4.30; N, 9.20. Found: C, 39.35; H, 4.48; N, 9.01. ESI MS (m/z)
(L ¼ Ligand): 572.99 [L þ 2Ag þ Cl]þ, 467.10 [L þ Ag þ Cl þ H]þ,
323.22 [L þ H]þ. IR: nmax(solid)/cmꢀ1: 3087w, 2984w, 2929w,
2867w, 1605m, 1560w, 1497m, 1458m, 1412m, 1369m, 1258m,
1228m, 1196, 1110m, 1002w, 948w, 871w, 732s, 692s, 511w, 434w,
409w, 294w, 259w, 236w, 218w, 162w, 154w.
(300 MHz, CD2Cl2):
d
11.56 (s, 2H, NCHN), 9.04 (t, J ¼ 2.0 Hz, 1H),
8.91 (t, J ¼ 1.8 Hz, 2H, CHimidazole), 8.24 (dd, J ¼ 8.3, 2.0 Hz, 2H), 7.72
(t, J ¼ 8.3 Hz, 1H, CHary), 7.60 (t, J ¼ 1.8 Hz, 2H, CHimidazole), 4.45 (t,
J ¼ 7.3 Hz, 4H, NCHB2u), 2.02 (quint resulting from overlapping tt,
J ¼ 7.5 Hz, 4H, CHB2u), 1.43 (sext resulting from overlapping qt),
J ¼ 7.5 Hz, 4H, CH2Bu, 1.00 (t, J ¼ 7.3 Hz, 6H, CHB3u). 13C{1H} NMR
Synthesis of bis(
tetra-m3-bromotetrasilver(I) (2b)
m k-C)
-1,3-bis(30-butylimidazol-20-ylidene)benzene-
(126 MHz, CD2Cl2):
d
137.0 (Caryl), 136.5 (NCHN), 133.0 (CHaryl),
123.4 (CHimidazole), 122.8 (CHaryl), 122.4 (CHimidazole), 115.5 (CHaryl),
51.0 (NCHB2u), 32.4 (CH2Bu), 20.1 (CH2Bu), 13.8 (CHB3u).
A procedure similar to that used for compound 2a with 1b
(1.66 g, 3.44 mmol) and Ag2O (1.19 g, 5.16 mmol) gave 2b as a white
powder (1.47 g, 1.05 mmol). Yield: 61%. Crystals suitable for X-ray
analysis were grown by slow evaporation of a solution mixture of
Synthesis of 1,10-(1,3-phenylene)bis(3-butyl-1H-imidazol-3-ium)
iodide (1c) [54,71,95]
A procedure similar to that used for compound 1a with 1,3-
di(imidazol-1-yl)benzene (4.00 g, 19.0 mmol) and n-butyl iodide
(10.0 mL, 87.9 mmol) in refluxing THF, for 48 h, gave 1c as an off-
white powder (7.48 g, 12.9 mmol). Yield: 68%. 1H NMR (300 MHz,
2b/CH2Cl2/octane. 1H NMR (300 MHz, CD2Cl2):
d 7.88 (m, 1H,
CHaryl), 7.62 (d, J ¼ 1.9 Hz, 2H, CHimidazole), 7.59 (d, J ¼ 2.0 Hz, 2H,
CHaryl), 7.45 (dd, J ¼ 8.6, 7.4 Hz, 1H, CHaryl), 7.26 (d, J ¼ 1.9 Hz, 2H,
CHimidazole), 4.22 (t, J ¼ 7.3 Hz, 4H, NCH2Bu), 1.96e1.84 (m, 4H, CHB2u),
1.42 (m, 4H, CH2Bu), 0.99 (t, J ¼ 7.3 Hz, 6H, CHB3u). 13C{1H} NMR
CD2Cl2):
d
11.25 (s, 2H, NCHN), 8.97 (t, J ¼ 2.1 Hz, 1H, CHaryl), 8.48 (t,
(126 MHz, CD2Cl2): d
182.7 (Ccarbene), 141.5 (Caryl), 131.4 (CHaryl),
J ¼ 1.9 Hz, 2H, CHimidazole), 8.14 (dd, J ¼ 8.1, 2.2 Hz, 2H, CHaryl), 7.87 (t,
J ¼ 6.3 Hz, 1H, CHaryl), 7.51 (t, J ¼ 1.9 Hz, 2H, CHimidazole), 4.46 (t,
J ¼ 7.4 Hz, 4H, NCH2Bu), 2.11e2.00 (m, 4H, CH2Bu), 1.47 (m, 4H, CH2Bu),
124.1 (CHaryl), 122.6 (Cimidazole), 122.4 (Cimidazole), 120.5 (CHaryl), 52.7
(NCHB2u), 33.9 (CH2Bu), 20.3 (CH2Bu), 14.0 (CHB3u). Anal. Calc. for
C20H26N4Ag2Br2: C, 34.42; H, 3.75; N, 8.03. Found: C, 35.02; H, 3.76;
1.02 (t, J ¼ 7.3 Hz, 6H, CHB3u). 13C{1H} NMR (75 MHz, CD2Cl2):
d
136
N, 8.41. ESI MS (m/z) (L ¼ Ligand): 1314.18 [2L þ 4Ag þ 3Br]þ,
1208.88 [2L þ 3Ag þ 3Br þ H]þ, 1126.96 [2L þ 3Ag þ 2Br]þ, 939.15
[2L þ 2Ag þ Br]þ, 616.94 [L þ 2Ag þ Br]þ, 511.06 [L þ Ag þ Br þ H]þ,
430.12 [L þ 2Ag]2þ. IR: nmax(solid)/cmꢀ1: 3088w br, 2928m br,
2867w, 1604m, 1561m, 1497m, 1460m, 1411m, 1369m, 1257m,
1227m, 1196m, 1108m, 1059m, 1001w, 948w, 872m, 729s, 692s,
507w, 435w, 303w, 280w, 247w, 150w, 118w.
0.6 (NCHN), 136.3 (Caryl), 133.3 (CHaryl), 123.5 (CHimidazole), 123.4
(CHaryl), 122.3 (CHimidazole), 116.5 (CHaryl), 51.1 (NCH2Bu), 32.4 (CH2Bu),
20.0 (CHB2u), 13.7 (CHB3u).
Synthesis of 1,10-(1,3-phenylene)bis(3-butyl-1H-imidazol-3-ium)
tetrafluoroborate (1d)
To a solution of 1,3-bis(30-butylimidazol-l-yl)benzene dibro-
mide (1b) (0.11 g, 0.23 mmol) in acetone was added an excess of
NaBF4 (0.26 g, 2.37 mmol). The mixture was stirred at room tem-
perature overnight. NaBr was removed by filtration through Celite®
and the filtrate was precipitated with pentane, yielding a clean
product (0.12 g, 0.24 mmol). Yield: 98%. 1H NMR (500 MHz, CD2Cl2):
Formation of 2b from (1,3-bis(30-butylimidazol-20-ylidene)benzene)
disilver(I) dichloride (2a)
The complex 2a (0.66 g, 1.09 mmol), LiBr (0.19 g, 2.19 mmol) and
dry acetone were combined and stirred for 18 h under inert at-
mosphere. The solvent was evaporated and the solid was dissolved
in CH2Cl2. The solution was filtered through Celite® and concen-
trated under reduced pressure. The complex 2b was isolated
(0.75 g, 0.54 mmol) upon precipitation with pentane. Yield: 98%.
d
9.69 (s, 2H, NCHN), 8.26 (t, J ¼ 2.1 Hz,1H, CHaryl), 8.09 (t, J ¼ 1.9 Hz,
2H, CHimidazole), 7.88 (dd, J ¼ 8.2, 2.0 Hz, 2H, CHaryl), 7.76 (t,
J ¼ 4.8 Hz, 1H, CHaryl), 7.57 (t, J ¼ 1.9 Hz, 2H, CHimidazole), 4.32 (t,
J ¼ 7.4 Hz, 4H, NCH2Bu), 1.98e1.91 (m, 4H, CH2Bu), 1.40 (m, 4H, CH2Bu),
0.96 (t, J ¼ 7.4 Hz, 6H, CHB3u). 13C{1H} NMR (126 MHz, CD2Cl2):
Synthesis of bis(
tetra-m3-iodotetrasilver(I) (2c) [71]
m k-C)
-1,3-bis(30-butylimidazol-20-ylidene)benzene-
d
136.4 (NCHN),135.5 (Caryl), 133.2 (CHaryl), 123.9 (CHimidazole), 123.6
(CHaryl), 122.2 (CHimidazole), 116.5 (CHaryl), 51.1 (NCH2Bu), 32.2 (CH2Bu),
A procedure similar to that used for compound 2a with 1c
(1.00 g, 1.73 mmol) and Ag2O (0.60 g, 2.59 mmol) gave 2c as a white
powder (2.05 g, 1.29 mmol). Yield: 75%. 1H NMR (300 MHz, CD2Cl2):
19.9 (CHB2u), 13.6 (CH3Bu). 19F NMR (282 MHz, CD2Cl2):
BFꢀ4 ).
d
ꢀ149.3 (s,
d
8.38 (t, J ¼ 1.8 Hz, 1H, CHaryl), 7.58e7.47 (m, 2H, CHaryl), 7.47e7.36
Synthesis of (1,3-bis(30-butylimidazol-20-ylidene)benzene)disilver(I)
dichloride (2a)
(m, 3H, CHaryl þ CHimidazole), 7.17 (d, J ¼ 1.5 Hz, 2H, CHimidazole), 4.25
(t, J ¼ 7.1 Hz, 4H, NCH2Bu), 1.83 (m, 4H, CH2Bu), 1.35 (m, 4H, CHB2u), 0.90
1,10-(1,3-phenylene)bis(3-butyl-1H-imidazol-3-ium) chloride
(1a) (0.68 g, 1.72 mmol) and Ag2O (0.60 g, 2.58 mmol), molecular
sieves (3 Å beads), and CH2Cl2 were combined, protected from light
and stirred for 18 h under argon at room temperature. The solution
was filtered through Celite®, evaporated under reduced pressure
and the solid was washed three times with distilled water. The
organic phase was dried over MgSO4 and filtered. Upon precipita-
tion with pentane, the complex was cleanly recovered (2.05 g,
1.29 mmol). Yield: 65%. Crystals suitable for X-ray analysis were
grown by slow evaporation from a solution mixture of 2a/CH2Cl2/
(t, J ¼ 7.3 Hz, 6H, CHB3u). 13C{1H} NMR (75 MHz, CD2Cl2):
d 184.8
(Ccarbene), 141.0 (Caryl), 130.4 (CHaryl), 123.2 (CHimidazole), 121.9
(CHaryl), 121.5 (CHaryl), 121.0 (CHimidazole), 52.0 (NCH2Bu), 33.5 (CH2Bu),
19.9 (CHB2u), 13.7 (CH3Bu). Anal. Calc. for C40H52N8Ag4I4: C, 30.33; H,
3.31; N, 7.07. Found: C, 30.01; H, 3.38; N, 6.88. ESI MS (m/z)
(L
¼
Ligand): 1584.68 [2L
þ
4Ag
þ
4I
þ
H]þ, 1456.76
[2L þ 4Ag þ 3I]þ, 1348.86 [2L þ 3Ag þ 3I þ H]þ, 1222.94
[2L þ 3Ag þ 2I]þ, 1115.05 [2L þ 2Ag þ 2I þ H]þ, 987.14
[2L þ 2Ag þ I]þ, 664.92 [L þ 2Ag þ I]þ, 559.03 [L þ Ag þ I þ H]þ,
430.12 [2L þ 2Ag]þ. IR: nmax(solid)/cmꢀ1: 3158w, 3104w, 3050w,
2954w, 2928w, 2869w, 1604w, 1541w, 1491m, 1463m, 1404m,
1378w, 1343w, 1266w, 1251w, 1221w, 1192w, 1097m, 1072w,
1001w, 946w, 883w, 850w, 821w, 792m, 763w, 721s, 696m, 631w,
505m, 452m, 379w, 307w, 238w, 156w.
octane. 1H NMR (300 MHz, CD2Cl2):
d
7.98 (m, 1H, CHaryl), 7.71
(apparent d, J ¼ 1.8 Hz, 3H, CHimidazole þ CHaryl), 7.66 (d, J ¼ 2.1 Hz,
2H, CHaryl), 7.23 (d, J ¼ 1.8 Hz, 2H, CHimidazole), 4.22 (t, J ¼ 7.3 Hz, 4H,
NCH2Bu), 1.94e1.83 (m, 4H, CH2Bu), 1.41 (m, 4H, CHB2u), 0.99 (t,
j.jorganchem.2015.01.025